跳至主要内容
临床试验/NCT02771353
NCT02771353已完成2 期

The HeartSpare Plus 1B Trial: A Randomised Phase II Trial Comparing the Resource Impact, Acute Toxicity and Feasibility of Different Pan-lymph Node Radiotherapy Techniques for Breast Cancer Patients

Royal Marsden NHS Foundation Trust0 个研究点目标入组 39 人开始时间: 2016年12月12日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
39
主要终点
Linear Accelerator time

研究概览

简要总结

This study aims to compare the resource impact, acute toxicity and feasibility of different pan-lymph node radiotherapy techniques. Radiotherapy using wide tangents with the patient in breath hold will be compared against volumetric modulated arc therapy (VMAT) in free breathing in the main trial. A parallel study will asses the accuracy of VMAT treatments using voluntary deep inspiratory breath hold compared to an active breathing controlled breath hold device.

详细描述

Following publication of results of two large randomised clinical trials, pan-lymph node radiotherapy (pan-LN RT) (including treatment of the internal mammary chain) is set to become standard treatment in patients with lymph-node positive breast cancer. Traditional pan-LN RT techniques deliver high radiation doses to the heart and lungs which can cause long-term side-effects in women many years after their treatment. Modern techniques including breath-holding and volumetric-modulated arc therapy (VMAT) can reduce doses to heart and lungs but the investigators do not yet know which technique(s) are best in terms of resource costs, short to medium-term side-effects, and day to day accuracy. This study will compare the time taken to deliver pan-LN RT using breath-holding versus VMAT and will collect side-effect data up to one year following treatment as well as modelling long-term cardiac risks based on heart doses delivered. The results of the main study will help guide clinicians and departments in selecting the best pan-LN RT techniques for their patients. A parallel study will evaluate the combination of breath-hold and VMAT using a machine-based technique called the active-breathing controlled (ABC) device against a more simple voluntary breath-hold technique were patients simply take a breath in and hold it for up to 20 seconds at a time. These techniques will be compared in terms of their day-to-day accuracy. If the simpler technique proves as accurate as the ABC-technique, this will establish the simpler technique as a less resource-intensive standard of care adoptable by other radiotherapy departments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥18 years
  • Female or male
  • Invasive carcinoma of the breast (left or right-sided)
  • Breast conservation surgery or mastectomy
  • Axillary staging and/or dissection
  • pT1-T4,N1-2,M0 disease
  • Histological involvement of axillary lymph nodes
  • Indication for radiotherapy to the IMC, axillary levels I-III and/or level IV
  • Patient able to tolerate breath hold
  • Performance status 0-1

排除标准

  • Contralateral and/or previous ipsilateral breast cancer, irrespective of date of diagnosis
  • Past medical history of malignancy except (i) basal cell skin carcinoma, (ii) CIN cervix uteri, (iii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free
  • Previous radiotherapy to any region above the diaphragm

结局指标

主要结局

Linear Accelerator time

时间窗: 3 weeks

Patient mounting couch to linear accelerator being turned off

次要结局

  • Organ at risk dose - heart(Immediate)
  • Organ at risk dose - contralateral breast(Immediate)
  • Organ at risk dose - brachial plexus(Immediate)
  • Inter-fraction reproducibility(3 weeks)
  • Acute toxicity - fatigue(5 weeks)
  • Acute toxicity - quality of life(5 weeks)
  • Intermediate toxicity - lung (pneumonitis)(up to 1 year)
  • Intermediate toxicity - quality of life(up to 1 year)
  • Intermediate toxicity - lymphoedema/ shoulder dysfunction(up to 1 year)
  • Organ at risk dose - ipsilateral lung(Immediate)
  • Organ at risk dose - contralateral lung(Immediate)
  • Organ at risk dose - thyroid(Immediate)
  • Organ at risk dose - humeral head(Immediate)
  • Organ at risk dose - Left anterior descending coronary artery(Immediate)
  • Acute toxicity - lung (pneumonitis)(5 weeks)
  • Intermediate toxicity - fatigue(up to 1 year)
  • Organ at risk dose - oesophagus(Immediate)
  • Acute toxicity - Skin(5 weeks)
  • Acute toxicity - oesophagitis(5 weeks)
  • Time taken to plan and check radiotherapy(Immediate)

研究者

申办方类型
Other
责任方
Sponsor

相似试验